Insulin Degludec Classification
Insulin degludec belongs to the long-acting basal insulin analog family, specifically classified as an ultra-long-acting basal insulin analog. 1
Detailed Classification
Insulin degludec is a long-acting basal human insulin analog produced through recombinant DNA technology in Saccharomyces cerevisiae followed by chemical modification 1. The molecular structure differs from human insulin in that:
- The amino acid threonine at position B30 has been omitted
- A side-chain consisting of glutamic acid and a C16 fatty acid has been attached
- Chemical name: LysB29(Nε-hexadecandioyl-γ-Glu) des(B30) human insulin 1
Pharmacologic Characteristics That Define Its Class
The classification as an ultra-long-acting basal insulin is based on its unique pharmacokinetic properties 2, 3:
- Half-life: Approximately 25 hours
- Duration of action: Greater than 42 hours at steady state
- Mechanism of prolonged action: Forms multi-hexamers when injected subcutaneously, creating a depot with delayed absorption and albumin binding 1
Clinical Context
Current diabetes management guidelines categorize insulin degludec among the longer-acting basal analogs (specifically U-300 glargine or degludec), which convey lower nocturnal hypoglycemia risk compared to U-100 glargine 4. The 2024 guidelines distinguish it from other long-acting analogs (U-100 glargine and detemir) based on its extended duration profile 5.
Available formulations include U-100 (100 units/mL) and U-200 (200 units/mL) concentrations for subcutaneous injection 1.